EurekAlert! -
30 Jun 2014 06:00
(H. Lee Moffitt Cancer Center & Research Institute) Moffitt Cancer Center researchers developed a new way to identify possible therapeutic targets for patients with drug resistant melanoma. It involves using liquid chromatography-multiple reaction monitoring mass spectrometry to measure biomarkers or molecules in blood and tissue that indicates cancer is present. These measurements can help researchers determine if a patient is responding to treatment.
Share this Article